Navigation Links
Antidepressant and placebo are equally effective in child pain relief
Date:9/30/2009

Bethesda, MD (Oct. 1, 2009) When used "off-label," the antidepressant amitriptyline works just as well as placebo in treating pain-predominant gastrointestinal disorders in children, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. To view this article's video abstract, go to the AGA's YouTube Channel at www.youtube.com/AmerGastroAssn.

"Many pharmaceutical products are prescribed for off-label use in children due to the lack of clinical trials testing the efficacy of the drugs in children and adolescents. Therefore, the pediatric gastroenterologist frequently has to make treatment decisions without the evidence of how drugs work in children," said Miguel Saps, MD, of Children's Memorial Hospital and lead author of the study. "The high placebo effect we identified in this study suggests that further studies of the use of certain antidepressants in children with functional bowel disorders are needed. While several trials have demonstrated a beneficial effect of antidepressants, including amitriptyline, for the treatment of irritable bowel syndrome (IBS) in adults, more research is needed to determine how effective this drug is, if at all, in children."

Amitriptyline (Elavil) is used to treat symptoms of depression, however, it is often times prescribed to children for pain relief from pain-predominant functional gastrointestinal disorders (FGIDs). Pain-predominant FGIDs are among the most common causes for medical consultation in children. Such disorders include three common conditions: IBS, functional dyspepsia and functional abdominal pain.

Doctors designed a large prospective, multicenter, randomized placebo-controlled trial in which children, ages eight to 17, with IBS, functional abdominal pain or functional dyspepsia were randomized to four weeks of placebo or amitriptyline.

Of the 83 children who completed the study, 63 percent
'/>"/>

Contact: Alissa J. Cruz
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Antidepressants Linked to Heart Defects in Newborns
2. Antidepressants: Benefit of SNRI is proven
3. Suicide Risk With Antidepressants Falls With Age
4. Labopharm submits response to FDA for novel antidepressant
5. Antidepressant Use in U.S. Has Almost Doubled
6. Almost 1 quarter of Spanish women take antidepressants
7. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
8. Antidepressants aid electroconvulsive therapy in treating severe depression
9. Preliminary report on antidepressants published
10. Some Antidepressants May Thwart Tamoxifens Effect on Breast Cancer
11. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 2014 Acute coronary syndrome (ACS) ... healthcare costs, frequent recurrences and hospitalizations, and high ... ACS incidence increases with age and will be ... population increases around the world. ACS is classified ... heart muscle damage inferred from a person’s symptoms, ...
(Date:7/14/2014)... 14, 2014 Georgia State University ... groups under the fifth round of its Second ... of research and academic performance. , The ... of top-notch faculty members to the university, with ... in areas of national significance. , “With the ...
(Date:7/14/2014)... through the bloodstream, homing in on a sheath ... and metastasize to other organs, scientists at The ... in Cancer Cell . , "This completely ... provides new potential avenues to predict and prevent ... M.D., professor of Gynecologic Oncology and Reproductive Medicine ...
(Date:7/14/2014)... look back on 40 years of the Glasgow Coma Scale ... and clinical practice, in a new Personal View published in ... Personal View is published on the 40th anniversary of the ... Since this seminal publication, the Glasgow Coma Scale has provided ... level, the clinical hallmark of acute brain injury. The scale ...
(Date:7/14/2014)... D.C., July 14, 2014 A recent study published ... of the American Academy of Child and Adolescent Psychiatry ... the age of onset criterion for diagnosis of attention-deficit/hyperactivity ... for ADHD, previously set at 7 in DSM-IV, has ... of onset is now set at 12, rather than ...
Breaking Medicine News(10 mins):Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 2Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 3Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 4Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 2Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 3Health News:MD Anderson researchers discover new route for ovarian cancer spread 2Health News:MD Anderson researchers discover new route for ovarian cancer spread 3
... a novel study on condom use with help from ,scientists, ... the significance of condom use in curtailing spread of AIDS. ... study on a request from Pope Benedict XVI. The cardinal ... abstinence from sex in the fight against AIDS. ...
... has been approved by the Food and Drug Administration ... cyanide poisoning//. The kit contains the drug hydroxocobalamin, intravenous ... enables emergency treatment for known or suspected cyanide poisoning. ... to emergencies including possible attacks by terrorists is enhanced. ...
... people seeking medical help because of illnesses related to alcohol ... few years//. ,Current official statistics show that ... treated for accidents and emergencies caused due to drunkenness ... for the same also have doubled, reported NHS since 1997, ...
... given rise not only to high expectations of treatment ... the German Research Foundation, Deutsche Forschungsgemeinschaft (DFG) issued its ... developed enormously. ,The second memorandum, which ... on Genetic Research, makes it clear that gene therapy ...
... research study finds that 95 percent of Americans have pre ... new as American men //and women as far back as ... disappointed that spending hundreds of millions of dollars advising young ... being wasted. One official disagreed and opined that even if ...
... ingredient of psychedelic mushrooms, also called magic mushrooms ... disorder (OCD), according to a study// by University ... substances like psilocybin, psilocin, or muscimol. ,The ... 1970, according to AP reports. ,The intent ...
Cached Medicine News:Health News:Gene Therapy for Hereditary Immunodeficiency Diseases 2
(Date:7/14/2014)... July 14, 2014  Mylan Inc. (NASDAQ: MYL ... agreement with Abbott (NYSE: ... non-U.S. developed markets specialty and branded generics business ("the ... will receive 105 million shares of the combined ... of $50.20 on Friday, July 11, 2014, representing an approximately ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... 11, 2010 Thoratec Corporation (Nasdaq: THOR ... therapies to save, support and restore failing hearts, said ... Tuesday, November 16 at the American Heart Association (AHA) ... and chief executive officer of Thoratec, will be discussing ...
... 2010 Ardea Biosciences, Inc. (Nasdaq: RDEA ... trials of BAY 86-9766 (formerly known as RDEA119) will ... and Treatment of Cancer (EORTC) – National Cancer Institute ... on "Molecular Targets and Cancer Therapeutics" in Berlin, Germany. ...
Cached Medicine Technology:Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 3Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 4